Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.

BMC veterinary research - 7 Apr 2021

Tani Hiroyuki, Miyamoto Ryo, Noguchi Syunya, Kurita Sena, Nagashima Tomokazu, Michishita Masaki, Yayoshi Naoko, Tamura Kyoichi, Bonkobara Makoto

Abstract excerpt

BACKGROUND: Canine malignant melanoma is highly aggressive and generally chemoresistant. Toceranib is a kinase inhibitor drug that inhibits several tyrosine kinases including the proto-oncogene receptor tyrosine kinase KIT. Although canine malignant melanoma cells often express KIT, a therapeutic effect for toceranib has yet to be reported for this tumor, with only a small number of patients studied to date. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dog Diseases
Share to Dogs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Lymphatic Metastasis

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Source

Open in PubMed Open full text

Identifiers

PMID: 33827546
DOI: 10.1186/s12917-021-02864-3
PMCID: PMC8028755

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.PMID 33827546Read ↗

The caninized anti-canine PD-1 monoclonal antibody in canine oral malignant melanoma: Efficacy and exploratory biomarker analysisSemantic proximity Read ↗

Longitudinal transcriptomic and genetic landscape of radiotherapy response in canine melanomaSemantic proximity Read ↗

Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas.Semantic proximity Read ↗

Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.Semantic proximity Read ↗

Single institution study of the immune landscape for canine oral melanoma based on transcriptome analysis of the primary tumorSemantic proximity Read ↗

c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.Semantic proximity Read ↗

A case report of feline mast cell tumour with intertumoral heterogeneity: Identification of secondary mutations c.998G>C and c.2383G>C in KIT after resistance to toceranib.Semantic proximity Read ↗

KIT Somatic Mutations and Immunohistochemical Expression in Canine Oral MelanomaSemantic proximity Read ↗

Detection of novel polymorphisms in the ckit gene of canine patients with lymphoma, melanoma, haemangiosarcoma, and osteosarcoma.Semantic proximity Read ↗

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatmentSemantic proximity Read ↗

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.Semantic proximity Read ↗

Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.